ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Holland Recovering From Coronary Bypass; Henry Kaplan Receives Annual Prentis Award

July 25, 1980

Copeland Named Director, UF Cancer Center

February 10, 1995

Private Sector Still Valuable To National Cancer Program, ACS Research Chief Says

April 26, 1974

Foundations Invites Antitobacco Proposals

October 15, 1993

Cancer Patient Medical history System Proposed

July 13, 1979

Upton Considers Moving Basic Research Contracts To grants; Staff Changes Possible, Newell Stay

July 22, 1977